ArticleActa pharmacologica Sinica2026
The multilevel exploration test, a novel paradigm to measure exploratory behavior in depression animal models and the involvement of the PL-ZI circuit.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diminished drive is one of the core symptoms of major depressive disorder (MDD) diagnosis, yet its underlying neural mechanisms remain elusive, primarily due to a lack of appropriate animal models. We developed a novel Multilevel Exploration Test (MET) apparatus to evaluate exploratory behavior, which is captured as a dynamic, stage-dependent process involving "search", "attend/investigate", and "approach" phases. We employed fiber photometry to measure real-time dopamine dynamics in the nucleus accumbens. We further combined cFos staining and neural circuit tracing to identify relevant brain regions and circuits, and employed chemogenetics to selectively modulate prelimbic cortex (PL) inputs to zona incerta (ZI). The MET tests were conducted across five depression models, with ketamine administration to evaluate rescue effects. Machine learning algorithms were utilized to analyze MET data and predict individual emotional states (normal, anxiety-like, depression-like). Here, we developed a novel paradigm to assess exploratory behavior, which demonstrates etiological validity, face validity and predictive validity. Depressed mice exhibited reduced motivation for exploration in this paradigm, while stimulation of the PL-ZI circuit not only restored exploratory deficits but also alleviated other depression-like behaviors in these mice. Furthermore, we established a machine learning-based model to predict individual animals' emotional states by integrating data from the new paradigm, achieving a prediction accuracy of over 92%. The MET provides a functional, high-throughput paradigm for dissecting motivation-related pathology. It facilitates the assessment of depressive-like behaviors, enables the prediction of emotional states, and supports the discovery of novel targets for antidepressant development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.